1. Introduction {#sec1}
===============

Recurrent episodes of binge eating and purging behavior occur in both anorexia nervosa, binge−purge subtype (AN−BP) and bulimia nervosa (BN). In women, the lifetime prevalence of AN and BN is 0.9% and 1.5% respectively ([@ref1]). Eating disorders, in particular AN, have among the highest mortality rate of all psychiatric disorders ([@ref2]), and treatment options are limited for severe forms of AN and BN, particularly for AN−BP ([@ref3]). Conventional treatments include psychotherapy, pharmacotherapy and inpatient treatments, but rates of treatment dropout, limited treatment response and relapse rates are substantial ([@ref4]; [@ref5]; [@ref6]; [@ref7]; [@ref8]). New treatment options are urgently needed.

Therapeutic brain stimulation is a novel approach in treatment-refractory eating disorders (ED), as recently demonstrated in a pilot study using deep brain stimulation (DBS) in AN ([@ref9]). Non-invasive techniques such as repetitive transcranial magnetic stimulation (rTMS) would offer greater accessibility and lower medical risk than DBS, if suitable stimulation targets could be identified. Neuroimaging research has identified a variety of neuroanatomical substrates of ED pathophysiology. For example, on structural imaging, ED patients show reductions in gray matter volume in regions involved in reward, impulse control, and emotion regulation: the caudate nucleus, ventral striatum (VS), anterior cingulate (ACC) and orbitofrontal cortex (OFC) ([@ref10]; [@ref11]; [@ref12]; [@ref13]). Likewise, functional magnetic resonance imaging (fMRI) studies in ED reveal abnormal patterns of resting-state connectivity in the default-mode network ([@ref14]) and other intrinsic brain networks incorporating the ACC and insula ([@ref15]). ED patients also show abnormal VS activation in response to rewarding and aversive stimuli ([@ref16; @ref17]). Patients with BN show hyperactivity in medial frontal lobe regions during inhibition of prepotent actions ([@ref18]), and hypoactivity in response to food cues ([@ref19]).

Among the various neural substrates implicated in ED pathology, a target of particular interest that is accessible to rTMS is the dorsomedial prefrontal cortex (dmPFC). The dmPFC plays an important role in forms of self-control, including self-inhibition of movements ([@ref20]), self-cessation of loss-chasing in pathological gamblers ([@ref21]), self-suppression of emotional responses ([@ref22]), and impulse control ([@ref23]). Likewise, non-invasive stimulation of medial prefrontal areas, via rTMS, enhances inhibitory control over prepotent responses ([@ref24]), improves subjective choice for delayed rewards in a delayed discounting task, and interferes with striatal dopamine ([@ref25]). In sum, stimulation of the medial prefrontal cortex using rTMS may alter the top-down executive control of the dmPFC to striatal regions associated with the urge to binge and purge, thereby improving symptom severity.

Considering this literature on the role for the DMPFC in self-regulation, one potential implication is that DMPFC-rTMS might be worth exploring as a therapeutic approach for addressing self-regulatory deficits in ED. To date, most previous rTMS studies in ED have focused on the conventional target, the left dorsolateral prefrontal cortex (dlPFC). Although dlPFC-rTMS reduces cue-induced food craving in BN ([@ref26]; [@ref27]), a double-blind trial of dlPFC-rTMS for binge−purge symptoms found no significant improvement over sham ([@ref28]).

There are few reported studies of dmPFC-targeted rTMS to date. However, we recently investigated dmPFC-rTMS in major depression (MDD), finding efficacy rates comparable to dlPFC-rTMS, but with sharply dichotomous outcomes of improvement ([@ref29]). Using resting-state functional MRI (rsfMRI), we found that low dmPFC--subcortical connectivity predicted successful outcome, and that symptomatic improvements were associated with increased dmPFC connectivity. We also reported the serendipitous finding of full remission from binge−purge symptoms during dmPFC-rTMS for comorbid depression, in a patient with treatment-refractory BN ([@ref30]). These observations suggested that dmPFC-rTMS might treat a subset of BN patients, and that enhanced frontal−subcortical connectivity on rsfMRI might accompany symptomatic improvement.

Here we used rsfMRI to identify patterns of functional connectivity associated with response to dmPFC-rTMS, delivered as an intervention-probe to a series of 28 ED patients with treatment-refractory binge and purge behaviors. Based on our previous findings, we formulated two hypotheses: first, that lower baseline dmPFC connectivity on rsfMRI would predict successful treatment; second, that successful treatment would be associated with increases in connectivity through a fronto-subcortical circuit incorporating the dmPFC.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

28 subjects (26 female, age range = 20 − 56 years, mean = 31.0 ± 9.5 years) meeting DSM-5 criteria for AN−BP (n = 11), BN (n = 17) participated in this proof-of-concept, open-label study. Subjects included individuals with bingeing and purging behavior, both at a normal and lower than normal weight. BMI ranged from 14.5--28.8. AN−BP participants displayed both bingeing and purging behaviors. While there are certainly important differences in the clinical features of these disorders (e.g., failure to maintain normal body weight, or the presence of restricting symptoms), binge and purge behaviors were the specific target symptom for the purposes of this pilot study. Subjects engaged in ≥2 cumulative objective binge/purge episodes weekly at baseline to be included in the study. Diagnoses were established through interviews with 2 independent, Canadian Royal College-certified psychiatrists (authors JD, PG, PC, BW). In recognition of the high prevalence of psychiatric comorbidities in this population, and in order to characterize rather than minimizing sample heterogeneity, common comorbidities were not excluded This inclusion of comorbidities is in line with our previous work in MDD ([@ref29]). Comorbid diagnoses included MDD (n = 16), obsessive--compulsive disorder (n = 6), post-traumatic stress disorder (n = 8), and bipolar disorder (n = 6). Patients with a history of a psychotic disorder, neurological disorder, active substance abuse, or contraindications to MRI or rTMS were excluded. All subjects had no improvements in bingeing/purging to or were unable to tolerate at least 1 previous medication trial (n = 27), and had also not responded to previous inpatient/outpatient treatment courses in terms of an improvement of binges and purges (n = 25). On average, patients had not respond to 2.61 ± 2.44 inpatient/outpatient treatments, and 3.00 ± 2.37 medication trials. Current medications included SSRIs (n = 11), antipsychotics (n = 11), benzodiazepines (n = 8), trazodone (n = 5), and SNRIs (n = 3). As routinely stipulated ([@ref31]), subjects were required to refrain from any medication changes during and for ≥4 weeks before rTMS.

2.2. Clinical outcomes {#sec2.2}
----------------------

The clinical outcome of interest, weekly frequency of binge and purge episodes, was monitored via a structured clinical interview, the Eating Disorder Examination (EDE), administered 1 week before treatment, at each week during treatment, and at 4 weeks post-treatment. For the purposes of stratification, response was defined as ≥50% decrease in objective binge (\>1000 calories per binge) and purge episode frequency from pre-rTMS to 4 weeks post-rTMS (at follow-up). Pre-treatment EDE assessments acquired binge/purge frequency for the 4 weeks prior to treatment, and the post-treatment EDE acquired frequency for the 4 weeks following treatment, and so the pre- and post-treatment scores were obtained from weeks outside of the rTMS treatment sessions. Data on bingeing and purging frequencies derived from the EDE was divided by 4 to generate a weekly frequency for bingeing and purging. To obtain weekly scores, EDE frequencies (which measure severity over 4 weeks) were divided over the 4 weeks. Although a more conservative criterion is sometimes used in clinical efficacy studies, our primary aim was to characterize and distinguish the neural activity of subpopulations of patients showing improvement versus non-improvement in this population. A set of clinical and psychometric data, including the 17-item Hamilton Rating Scale for Depression (HamD~17~), Beck Depression Index-II (BDI-II) and Beck Anxiety Index (BAI) were also collected as secondary metrics. To assess the distribution of outcomes across the study sample, we employed kernel density estimation by applying the Epanechnikov kernel ([@ref32]) in Stata13 (StataCorp). Two-tailed t-tests (Bonferroni-adjusted) were performed to determine the significance of differences in clinical measures between groups and between timepoints. The nonparametric Mann--Whitney *U* test was performed for comparisons of binge and purge frequency do to the markedly non-normal distribution of these data.

2.3. Neuroimaging acquisition {#sec2.3}
-----------------------------

The neuroimaging protocol followed parameters reported in detail in our previous studies of rsfMRI with dmPFC-rTMS ([@ref29]; [@ref31]). All subjects underwent 3 T MRI the week prior to and the week after rTMS, with a T1-weighted (TE = 12 ms, TI = 300 ms, flip-angle = 20°, 0.94 × 0.94 × 1.5 mm voxels) and a 10-min eyes-open resting state functional MRI scan (TE = 30 ms, TR = 2000 ms, flip-angle = 85°, 3.4 × 3.4 × 5 mm voxels).

2.4. Neuronavigation and rTMS treatment {#sec2.4}
---------------------------------------

Neuronavigation and rTMS treatment followed our previously reported protocols for dmPFC-rTMS in MDD ([@ref29]; [@ref31]). Neuronavigation employed the Visor 2.0 system (Advanced Neuro Technologies, Enschede, Netherlands) to target the stereotaxic coordinate (X = 0, Y = +30, Z = +30) in Talairach space ([@ref33]). rTMS employed the MagPro-R30 system (MagVenture, Farum, Denmark) and a Cool-DB80 coil. Motor thresholds were determined via contractions of the extensor hallucis longus ([@ref34]). Stimulation of the dmPFC was delivered at 120% resting motor threshold, at 10 Hz, 5 s on, 10 s off, 3000 pulses/hemisphere, with left then right lateralized coil orientation ([@ref35]). Unilateral stimulation was achieved by orienting the coil vertex at the stereotactic target laterally, with current flow oriented towards the desired hemisphere ([@ref36]). If a patient missed an rTMS session for logistical reasons, an additional session was added at the end of the course of treatment (no patient required more than 4 such sessions). Patients underwent 20 sessions of dmPFC-rTMS on weekdays; responders with any residual binge/purge symptoms were extended to 30 sessions (mean = 21.2 ± 3.7 sessions, range = 18--30).

2.5. MRI preprocessing, seed selection and statistical analysis {#sec2.5}
---------------------------------------------------------------

Preprocessing of resting-state fMRI data from patients employed FSL ([@ref37]), following methods as reported in our previous dmPFC-rTMS studies ([@ref31]) for slice-timing correction, segmentation, motion correction, spatial smoothing (6 mm FWHM Gaussian kernel), correction for white matter and cerebrospinal fluid signal artifacts, bandpass filtering (0.009--0.09 Hz), and linear co-registration to the MNI-152 template.

Seed regions-of-interest (ROIs) were defined a priori from the parcellation atlas of [@ref38] for the dmPFC and adjacent dorsal ACC (dACC) based on proximity to the stimulation target, following our analyses in a previous study of dmPFC-rTMS in MDD ([@ref31]). The seeds are described in detail in that study; their centroids were MNI = −4, 44, 42 for dmPFC and MNI = 0, 38, 24 for dACC (see [Figs. 2 and 3](#f0010 f0015){ref-type="fig"} for images of the ROIs). For first-level analysis, each seed ROI was co-registered to each subject\'s brain via nonlinear transformation, then applied as masks to extract the mean ROI time series. These time series were used to generate whole-brain maps of positively and negatively correlated voxels with the seed ROI before and after treatment, via a linear regression analysis using a fixed effects model at the individual-subject level.

Group level analysis was performed using FSL\'s FLAME mixed effects model ([@ref39]). We first identified regions where the degree of correlation at baseline to the ROIs differed significantly between responders and non-responders. To assess whether differing changes in resting-state connectivity over treatment would be associated with different outcomes, we then compared pre- and post-treatment scans to identify regions where the pre- to post-treatment change in correlation to the seed ROIs differed significantly between responders and non-responders. The results of these analyses were transformed into z-score maps, correcting for multiple comparisons using a Gaussian random field theory cluster-based correction (z-score \> 1.96, cluster significance p \> 0.05, corrected). Finally, the clusters previously obtained from group-level baseline predictor and change analyses were co-registered to patients\' individual scans, and connectivity values were extracted for each subject.

3. Results {#sec3}
==========

3.1. Primary clinical outcomes {#sec3.1}
------------------------------

No serious or treatment-limiting adverse effects occurred, and subjects reported only the localized scalp discomfort and transient headache routinely associated with rTMS treatment sessions.

Baseline binge and purge episode frequency per week was 11.1 ± SD 18.6 and 17.6 ± SD 31.7 ([Table 1](#t0005){ref-type="table"}). Combining both subpopulations, there was no significant overall change in binge frequency (post-rTMS mean = 8.6 ± 2.9, mean percent improvement = 20.4 ± 77.0, Wilcoxon signed-rank W~27~ = 1.29, p = 0.20) but a significant decrease in purge frequency was found (post-rTMS mean = 20.33 ± 10.2, mean percent improvement = 35.7 ± 62.1, Wilcoxon signed-rank W~27~ = 2.20, p = 0.03). 16 of 28 subjects achieved ≥50% reduction in binge and purge frequency from baseline to follow-up. However, outcomes were widely divergent across individuals, ranging from full remission to marked worsening of symptoms ([Fig. 1](#f0005){ref-type="fig"}). The degree of improvement across individuals followed a non-normal distribution (Shapiro--Wilk W~27~ = 0.85, p = 0.001). For this reason, subsequent analyses were performed to characterize responder and non-responder subpopulations separately.

Among responders, symptom frequency improved from 7.5 ± SD 5.4--1.4 ± SD 1.9 binge episodes/week (Wilcoxon signed-rank W~15~ = 3.39, p = 0.0007) and from 8.7 ± SD 6.9--1.3 ± SD 2.0 purge episodes/week (W~15~ = 3.49, p = 0.0005). Among non-responders, symptom frequency before and after treatment showed a nonsignificant worsening from 20.5 ± SD 26.8--18.3 ± SD 19.41 binge episodes/week (W~11~ = −1.30, p = 0.20) and 36.7 ± SD 44.3--54.5 ± SD 76.9 purge episodes/week (W~11~ = −0.59, p = 0.55). There was no significant difference between responders and non-responders at baseline for either binge (Mann--Whitney U~26~ = 0.91, p = 0.36) or purge (U~26~ = 1.21, p = 0.23) frequency. Further results pertaining to global and subscale changes on the EDE are reported in our supplementary document.

3.2. Psychometric outcomes {#sec3.2}
--------------------------

We also assessed the relationships between the following pre-treatment clinical measures and binge/purge percent improvement: baseline BMI, illness duration, baseline binge/purge severity, age, ED diagnosis (AN−BP or BN), presence of co-morbidity (MDD, obsessive--compulsive disorder, post-traumatic stress disorder, bipolar disorder), current medication (benzodiazepine, selective serotonin reuptake inhibitor, antipsychotic), and baseline severity and percent improvement of secondary measures (HamD~17~, BDI-II, BAI). No clinical measures, diagnoses, or medications predicted rTMS treatment response, or percent improvement in binge/purge frequency, either before or after Bonferroni correction for multiple comparisons (Spearman\'s rank correlation coefficient ρ~26~ \< 0.30, p \> 0.12 for each comparison above).

3.3. Functional connectivity predictors of response {#sec3.3}
---------------------------------------------------

Pre-treatment rsfMRI revealed significant differences between responders and non-responders from the dmPFC and dACC ROIs ([Fig. 2](#f0010){ref-type="fig"}). From the dmPFC seed, responders had significantly lower pre-treatment connectivity to bilateral temporal pole, OFC, and right posterior insula, and higher connectivity to bilateral lateral and medial occipital cortex ([Table 2](#t0010){ref-type="table"}). Pre-treatment functional connectivity from dmPFC to left and right lateral OFC was slightly positive in responders (z = 1.12 ± 0.56), and positive in both non-responders (z = 4.75 ± 0.56). Parameter estimates also revealed that pre-treatment functional connectivity from dmPFC to right insula was negative in responders (z = −3.36 ± 0.39) and non-responders (z = −0.20 ± 0.73) ([Fig. 2B](#f0010){ref-type="fig"}). Both dmPFC--insula and dmPFC--OFC connectivity at baseline were significantly anti-correlated to binge/purge percent improvement (r = −0.42 p = 0.03 and r = −0.46 p = 0.01, respectively).

From the dACC seed, responders had significantly lower pre-treatment connectivity to the right posterior insula, putamen, hippocampus, and middle temporal gyrus, and higher connectivity to superior parietal and medial occipital cortices and precuneus ([Table 2](#t0010){ref-type="table"}; [Fig. 2C](#f0010){ref-type="fig"}). Parameter estimates revealed that pre-treatment functional connectivity from dACC to right hippocampus was negative in responders (z = −3.69 ± 0.42), non-responders (z = −0.44 ± 0.46). Pre-treatment functional connectivity from dACC to right insula and thalamus was negative in responders (z = −3.15 ± 0.74) but positive in non-responders (z = 0.51 ± 0.53) ([Fig. 2D](#f0010){ref-type="fig"}). dACC--insula connectivity at baseline significantly anti-correlated to binge/purge percent improvement (r = −0.38 p = 0.01).

3.4. Functional connectivity changes associated with response {#sec3.4}
-------------------------------------------------------------

There were also significant differences between responders and non-responders in terms of the observed changes in functional connectivity to the dACC and dmPFC before and after treatment. Compared to non-responders, responders underwent significantly greater increases in functional connectivity between the dACC and bilateral caudate nucleus and VS, anterior insula, inferior frontal gyrus and adjacent OFC, and right putamen ([Table 3](#t0015){ref-type="table"}, [Fig. 3A](#f0015){ref-type="fig"}). Responders also showed greater increases in functional connectivity between the dmPFC and right middle temporal gyrus, and greater decreases in functional connectivity between the dmPFC and bilateral thalamus ([Table 3](#t0015){ref-type="table"}).

Inspection of parameter estimates revealed marked differences between responders and non-responders in how dACC--VS functional connectivity changed following treatment ([Fig. 3B](#f0015){ref-type="fig"}). The responder group showed lower functional connectivity between the dACC and VS prior to treatment, increasing significantly following successful treatment (t~12~ = 2.37, p = 0.035). Conversely, connectivity in non-responders decreased significantly (t~8~ = 2.316, p = 0.05), becoming significantly lower than treatment responders post-treatment (t~20~ = 2.409, p = 0.03). A similar pattern of significant increases in functional connectivity in responders (t~12~ = 3.314, p = 0.006), but decreases in functional connectivity in non-responders, trending to significance (t~8~ = 2.078, p = 0.07), was observed between the dACC and left anterior insula over the course of treatment ([Fig. 3B](#f0015){ref-type="fig"}). Binge/purge percent improvement was significantly correlated with the change in dACC--left anterior insula connectivity (r = 0.45, p = 0.04) and trended to significant correlation with the change in dACC--VS connectivity (r = 0.39, p = 0.07).

4. Discussion {#sec4}
=============

To our knowledge, this is the first report of neuroimaging findings in ED patients undergoing non-invasive brain stimulation. As an intervention-probe, dmPFC-rTMS divided patients into treatment-responsive and nonresponsive groups, with widespread differences in resting-state connectivity apparent between these groups at baseline. rTMS-responsive patients showed baseline hypoconnectivity from the stimulation target to other cortical and subcortical regions, relative to non-responders. In responders, frontostriatal connectivity was enhanced following dmPFC-rTMS, in association with improvement in binge and purge frequency. Conversely, in patients with higher baseline connectivity, the same intervention produced the opposite effect, reducing frontostriatal connectivity, in association with non-improvement or worsening of symptoms.

Of particular interest were the divergent trajectories of outcome across individuals. While many subjects showed marked improvement, a large proportion of subjects did not improve, or even showed deterioration, when exposed to the same intervention. The observation of divergent responses to dmPFC-rTMS in ED is in keeping with our previous report of a sharply bimodal distribution of responses to dmPFC-rTMS in MDD ([@ref29]). Of note, similarly dichotomous trajectories of improvement have been identified in clinical trials of duloxetine ([@ref40]) and escitalopram ([@ref41]).

The possibility of a neurobiological basis for the responder--non-responder dichotomy in the present study is supported by differences in resting-state functional connectivity observed between the two groups before treatment. In keeping with our first hypothesis, responders had significantly lower functional connectivity from the dmPFC and adjacent dACC to subcortical and cortical areas involved in emotion generation and regulation: hippocampus, lateral orbitofrontal cortex, and insula. These findings are consistent with several previous studies in MDD patients, linking baseline resting-state hypoconnectivity to better rTMS response ([@ref42; @ref43]; [@ref44]; [@ref31]).

Another key finding in the present study is that the same 10 Hz intervention had widely divergent effects on functional connectivity across individuals: patients with high baseline cortico-cortical and fronto-insular connectivity saw significant reductions after 10 Hz rTMS, while patients with low baseline frontostriatal and fronto-insular connectivity saw significant increases after stimulation at the same frequency. This phenomenon is unlikely to represent a regression to the mean, as the groups showed divergence rather than convergence in both symptomatology and functional connectivity over treatment. The results are also consistent with our previously reported observations of markedly dichotomous effects on striatal, thalamic and cortical functional connectivity from 10 Hz dmPFC-rTMS in patients with MDD ([@ref31]). The results are also consistent with previous studies of dlPFC-rTMS in depression: while some improved with high-frequency rTMS, others worsened on this regimen, and instead responded better to low-frequency stimulation of the same target ([@ref45]; [@ref46; @ref47]). These findings are consistent with mounting evidence that the physiological effects of a given rTMS protocol can vary widely across individuals, not just in magnitude but also in direction ([@ref48]; [@ref49]; [@ref50]; [@ref51]).

One limitation of this preliminary study involves its relatively small sample size. Though the sample was slightly larger than those used in several recent rTMS-fMRI studies in more prevalent disorders such as MDD ([@ref52]; [@ref44]; [@ref31]), the present study does not allow a more detailed characterization of potentially important clinical markers that could help distinguish treatment subpopulations. Although the present investigation did not find statistically significant pre-treatment differences between responders and non-responders in terms of duration of illness, BMI, and binge/purge frequency, future studies with higher power will be necessary to better assess whether those with more severe illness in general are less likely to respond to treatment. Another caveat relates to the inclusion of multiple DSM-5 diagnostic categories in the current sample, which embraced ED patients with binge−purge behaviors alongside common comorbidities. On this point, we note that the sample composition was chosen to be representative of clinical populations presenting with refractory binge−purge symptoms, and that no DSM-5 diagnosis significantly correlated with rTMS response. More generally, it is unclear that current categorical nosologies map particularly well on to rTMS responsiveness in general; the distinction between unipolar and bipolar depression had no bearing on outcome in a recent meta-analysis of rTMS efficacy ([@ref53]). We aware that some of our subjects were underweight, and that improvements in bingeing and purging represent a limited area of improvement for such individuals. However, given the exploratory nature of this trial, and the notorious difficulty in treatment individuals with ANBN, we felt it was important to include such individuals in the trial. It is clear that the question of whether dmPFC-rTMS aids other forms of disordered eating (including restrictive-type behaviors) is still an important area for future investigation.

Another potential criticism relates to the use of an open-label design without sham stimulation. Since no previous studies have examined dmPFC-rTMS in ED, and since the primary aim of the study was to apply an intervention-probe and characterize neural predictors and correlates of response (as in our recent work in depression), we opted for the present approach in order to identify sources of heterogeneity that might confound a future sham-controlled trial. The results suggest that three potentially critical confounds will need to be accommodated in future trials: first, the presence of distinct neural endophenotypes, not readily apparent on standard diagnostic criteria, but with differential responses to the intervention at both the neural and the clinical level; second, the need to tailor rTMS parameters to the individual patient in order to avoid paradoxical effects; third, whether predictors of improvement relate to illness mechanism, or a capacity to change with rTMS treatment, or both. Our results suggest that rsfMRI techniques help address both of these issues in any future randomized controlled study of rTMS in ED.

In conclusion, dmPFC-rTMS shows promising therapeutic effects in a subset of ED patients with refractory binge and purge behaviors. As in MDD, therapeutic effects are associated with increases in initially low levels of fronto-striatal functional connectivity, detectable on pre-treatment rsfMRI. However, a significant proportion of patients have initially higher baseline fronto-striatal connectivity, and in these patients, the same intervention produces paradoxical decreases in frontostriatal connectivity after treatment, alongside non-response or worsening of clinical symptoms. A randomized controlled trial of dmPFC-rTMS in ED would be a reasonable next step. However, the results of this study join a growing body of evidence ([@ref42]), suggesting that future trials of rTMS will need to take into account both the heterogeneity of individual patients\' neural activity, and the heterogeneity of effects ensuing from the stimulation itself. Pre-treatment neuroimaging may eventually play a crucial role in optimizing stimulation parameters, to maximize the chances of success in each patient presenting for treatment.
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![Probability distribution function of binge and purge percent improvement across all patients following dmPFC-rTMS.](gr1){#f0005}

![A: Regions with lower pre-treatment functional connectivity to the dmPFC seed (red) in responders versus nonresponders to dmPFC-rTMS. B: Parameter estimates for pre-treatment functional connectivity between the dmPFC seed and the bilateral orbitofrontal cortex (OFC) and right posterior insula in responders and non-responders prior to treatment. C: Regions with lower pre-treatment functional connectivity to the dACC seed (red) in responders versus nonresponders to dmPFC-rTMS. D: Parameter estimates for functional connectivity between the dmPFC seed and right hippocampus and posterior insula in responders and non-responders prior to treatment.](gr2){#f0010}

![A: Regions showing significantly greater increases in functional connectivity to the dACC seed from pre- to post-treatment in responders versus nonresponders to dmPFC-rTMS. B: Parameter estimates for functional connectivity between the dACC seed and the ventral striatum (right) and insula (left) in responders and nonresponders before and after undergoing dmPFC-rTMS.](gr3){#f0015}

###### 

Descriptive statistics for all patients, rTMS responders and non-responders.

                                       All subjects (n = 28)   rTMS responders (n = 16)   rTMS non-responders (n = 12)   Responder vs. non-responder difference (p)
  ------------------------------------ ----------------------- -------------------------- ------------------------------ --------------------------------------------
  Females (males)                      26 (2)                  15 (1)                     11 (1)                         *t*0.04 (0.97)
  Age                                  31.04 (±9.48)           30.75 (±8.23)              31.42 (±11.32)                 *t*0.04 (0.97)
  Duration of ED (years)               14.75 (±10.19)          12.75 (±7.51)              17.42 (±12.83)                 *t*0.84 (0.41)
  \# Prior treatments                  2.61 (±2.44)            2.63 (±2.06)               2.58 (±2.97)                   *t*0.04 (0.97)
  \# Prior medications                 3.00 (±2.37)            2.38 (±2.00)               3.83 (±2.66)                   *t*0.99 (0.33)
  \# of hospitalizations               3.57 (±4.20)            5.00 (±3.14)               6.42 (±5.35)                   *t*0.65 (0.52)
  Baseline BMI                         19.03 (±5.33)           19.81 (±3.68)              18.05 (±3.22)                  *t*1.35 (0.19)
  AN−BP (BN)                           12 (16)                 5 (11)                     7 (5)                          *t*0.87 (0.39)
  Weekly binge frequency (pre-rTMS)    11.14 (±18.59)          7.48 (±5.41)               20.55 (±26.82)                 U = 0.91 (0.36)
  Weekly purge frequency (pre-rTMS)    17.57 (±31.72)          8.75 (±6.93)               36.68 (±44.30)                 U 1.21 (0.23)
  Weekly binge frequency (post-rTMS)   8.32 (±15.09)           1.39 (±1.88)               18.25 (±19.41)                 U 4.12 (\<0.0001)\*\*
  Weekly purge frequency (post-rTMS)   19.63 (±53.96)          1.34 (±2.01)               54.53 (±76.93)                 U 3.51 (0.0004)\*\*

Abbreviations: AN−BP = Anorexia nervosa binge/purge subtype; BMI = body mass index; BN = bulimia nervosa; ED = eating disorders; rTMS = repetitive transcranial magnetic stimulation. Values indicate means, with standard deviations reported in brackets.

U indicates nonparametric significance testing using the Mann--Whitney *U*.

\*\* p \< 0.05.

###### 

Brain regions where pre-treatment functional connectivity to dmPFC and dACC seeds differed significantly between rTMS responders and nonresponders.

  Seed        Brain region                               Brodmann area   MNI coordinates   z           
  ------- --- ------------------------------------------ --------------- ----------------- ----- ----- ------
  dACC        Nonresponders \> responders                                                              
          R   Posterior insula                           13              44                −6    4     3.70
          R   Hippocampus                                                32                −28   −8    3.61
          R   Posterior superior/middle temporal gyrus   21/22           50                −18   −8    3.78
              Responders \> nonresponders                                                              
          R   Precuneus                                  7               10                −58   58    3.64
          L   Precuneus                                  7               −20               −58   60    4.00
          R   Intracalcarine cortex                      18              8                 −80   2     3.04
          B   Cuneus                                     18              8                 −90   22    3.11
  dmPFC       Nonresponders \> responders                                                              
          R   Lateral OFC                                25/47           34                24    −14   2.83
          L   Lateral OFC                                47              −34               22    −24   3.87
          R   Posterior insula                           13              38                −10   4     3.79
          L   Temporal pole                              28/38           −38               −10   −20   3.84
          R   Temporal pole                              28/38           52                4     −24   3.35
              Responders \> nonresponders                                                              
          B   Intracalcarine cortex, lingual gyrus       18              4                 −80   2     4.06

###### 

Brain regions where the change in functional connectivity to dACC and dmPFC seed from pre- to post-treatment differed significantly between rTMS responders and nonresponders.

  Seed        Brain region                                            Brodmann area   MNI coordinates   z           
  ------- --- ------------------------------------------------------- --------------- ----------------- ----- ----- ------
  dACC        Increased connectivity in responders \> nonresponders                                                 
          L   Caudate/ventral striatum                                                −14               18    2     3.89
          R   Caudate/ventral striatum                                                16                20    0     4.02
          R   Insula, putamen                                         13              32                −18   −2    4.03
          R   Anterior insula/OFC                                     13/47           36                18    −8    3.49
          L   Anterior insula/OFC                                     13/47           −38               14    2     3.16
          L   Inferior frontal gyrus                                  47              −34               22    −14   2.66
          B   Thalamus                                                                14                −18   14    3.13
  dmPFC       Increased connectivity in responders \> nonresponders                                                 
          R   Middle temporal gyrus                                   21/22           50                −26   −10   4.27
              Decreased connectivity in responders \> nonresponders                                                 
          B   Thalamus                                                                −4                −26   6     3.08
